Skip to main content Accessibility help
×
Home

Coumarin: an alternative candidate for the treatment of non-alcoholic steatohepatitis?

  • Jian Wu (a1)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Coumarin: an alternative candidate for the treatment of non-alcoholic steatohepatitis?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Coumarin: an alternative candidate for the treatment of non-alcoholic steatohepatitis?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Coumarin: an alternative candidate for the treatment of non-alcoholic steatohepatitis?
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

References

Hide All
1Larson-Meyer, DE, Newcomer, BR, Heilbronn, LK, et al. (2008) Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16, 13551362.
2Sanyal, AJ, Chalasani, N, Kowdley, KV, et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362, 16751685.
3de Luis, DA, Aller, R, Izaola, O, et al. (2010) Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 25, 730735.
4Musso, G, Gambino, R, Cassader, M, et al. (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79104.
5Malaguarnera, M, Gargante, MP, Russo, C, et al. (2010) l-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol 105, 13381345.
6Zein, CO, Yerian, LM, Gogate, P, et al. (2011) Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54, 16101619.
7Vitaglione, P, Morisco, F, Mazzone, G, et al. (2010) Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 52, 16521661.
8Chalasani, N, Younossi, Z, Lavine, JE, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 20052023.
9Matsuda, H, Murakami, T, Kageura, T, et al. (1998) Hepatoprotective and nitric oxide production inhibitory activities of coumarin and polyacetylene constituents from the roots of Angelica furcijuga. Bioorg Med Chem Lett 8, 21912196.
10Rajarajeswari, N & Pari, L (2011) Antioxidant role of coumarin on streptozotocin-nicotinamide-induced type 2 diabetic rats. J Biochem Mol Toxicol 25, 355361.
11Um, MY, Moon, MK, Ahn, J, et al. (2013) Coumarin attenuates hepatic steatosis by downregulating lipogenic gene expression in mice fed a high-fat diet. Br J Nutr 109, 15901597.
12Mielke, H, Abraham, K, Gotz, M, et al. (2011) Physiologically based toxicokinetic modelling as a tool to assess target organ toxicity in route-to-route extrapolation – the case of coumarin. Toxicol Lett 202, 100110.
13Felter, SP, Vassallo, JD, Carlton, BD, et al. (2006) A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol 44, 462475.

Coumarin: an alternative candidate for the treatment of non-alcoholic steatohepatitis?

  • Jian Wu (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed